Early pregnancy termination with antiprogestins: a comparative clinical study of RU 486 given in two dose regimens and Epostane.
Mifepristone, (RU 486, Roussel Uclaf, Romainville, France), a progesterone (P) receptor blocking agent, and Epostane, (WIN 32,729, Sterling-Winthrop, Guildford, United Kingdom), a P synthesis inhibitor, were compared for their ability to terminate early human pregnancy. Seventy-eight healthy women, with a gestational length of less than 49 days from the last menstrual period and who requested termination of pregnancy, were recruited to the study. The patients were randomly allocated to three treatment regimens: (1) Mifepristone 25 mg bid for 7 days; (2) Mifepristone 50 mg bid for 7 days; and (3) Epostane 200 mg qid for 7 days. The results of the study confirmed that both compounds are potent abortifacients in early human pregnancy. No difference in efficacy was seen between the two dose regimens of Mifepristone, which both resulted in 61% complete abortions. Seventy-three percent aborted completely in the Epostane group. Subjective side effects, especially nausea, were more common in the women treated with Epostane, but no serious side effects were seen.
D000028:Abortion, Induced; D000328:Adult; D000737:Androstenols / Q000009:adverse effects; D006063:Chorionic Gonadotropin / Q000097:blood; D004958:Estradiol / Q000097:blood; D004963:Estrenes / Q000008:administration & dosage / Q000009:adverse effects; D005260:Female; D005865:Gestational Age; D006801:Humans; D015735:Mifepristone; D011188:Potassium / Q000097:blood; D011247:Pregnancy; D011374:Progesterone / Q000097:blood; D011897:Random Allocation; D014508:Urea / Q000097:blood
D000737:Androstenols; D006063:Chorionic Gonadotropin; D004963:Estrenes; D015735:Mifepristone; D011374:Progesterone; D004958:Estradiol; C046855:epostane; D014508:Urea; D011188:Potassium